Format

Send to

Choose Destination
See comment in PubMed Commons below
Cancer Discov. 2012 Nov;2(11):979-81. doi: 10.1158/2159-8290.CD-12-0392.

Distinct epigenetic mechanisms distinguish TMPRSS2-ERG fusion-positive and -negative prostate cancers.

Author information

1
Oregon Health & Science University, Knight Cancer Institute, Portland, OR 97239, USA. alumkalj@ohsu.edu

Abstract

This issue of Cancer Discovery features an article that describes distinct epigenetic mechanisms that operate in TMPRSS2-ERG fusion-negative prostate cancers. This finding clarifies molecular features of these TMPRSS2-ERG fusion-negative tumors and may have implications for how to treat this prostate cancer subtype.

PMID:
23148372
PMCID:
PMC3661413
DOI:
10.1158/2159-8290.CD-12-0392
[Indexed for MEDLINE]
Free PMC Article
PubMed Commons home

PubMed Commons

0 comments
How to join PubMed Commons

    Supplemental Content

    Full text links

    Icon for HighWire Icon for PubMed Central
    Loading ...
    Support Center